{"id":"W2276335262","doi":"10.1016/j.jaad.2015.10.043","title":"Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults","year":2016,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":305,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Galderma; Astellas Pharma; Regeneron Pharmaceuticals; Genentech; Celgene; Valeant Pharmaceuticals International; Sanofi; Chugai Pharmaceutical; Pfizer; Amgen","keywords":"Medicine; Dupilumab; Atopic dermatitis; Quality of life (healthcare); Dermatology Life Quality Index; Anxiety; Eczema Area and Severity Index; Depression (economics); Severity of illness; Clinical trial; Generalizability theory; SCORAD; Disease; Internal medicine; Dermatology; Psychiatry","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001540267,0.0003471464,0.0007414497,0.000103185,0.0002290933,0.0005201019,0.0002141216,0.0003474655,0.001416086],"category_scores_gemma":[0.001513823,0.0001351625,0.0006045846,0.0002232794,0.0002019058,0.0003867701,0.0002248722,0.0008937351,0.0001364989],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003193001,"about_ca_system_score_gemma":0.0004657478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008830291,"about_ca_topic_score_gemma":0.002980802,"domain_scores_codex":[0.9993999,0.0003528306,0.00003740386,0.0000651064,0.00006518995,0.00007958553],"domain_scores_gemma":[0.9992777,0.0002953516,0.0001902733,0.00002854096,0.00004264303,0.0001655675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2972898,0.01148009,0.3089935,0.001655986,0.004575068,0.0008464216,0.0005386485,0.002247665,0.01691712,0.0007312433,0.01446803,0.3402565],"study_design_scores_gemma":[0.1050296,0.1243127,0.7403725,0.0002974455,0.00636243,0.002599673,0.0005391959,0.002639352,0.002263701,0.0009077614,0.01459426,0.0000813745],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911423,0.005615566,0.0001123612,0.0008365326,0.00004430303,0.00008822078,0.0006059131,0.00001110755,0.001543791],"genre_scores_gemma":[0.9968538,0.001570433,0.000222977,0.0005691539,0.0001118693,0.00004910479,0.0004101691,0.000002969775,0.0002096822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001540267,"threshold_uncertainty_score":0.008145869,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02186583079233416,"score_gpt":0.3439859349347897,"score_spread":0.3221201041424555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}